The Alzheimer's drug pipeline is healthier

It reflects a more nuanced understanding of the disease

阿尔茨海默病药物研发管线比你想象的更健康

这反映了对该疾病更细致入微的理解

Jun 3rd 2025

2025年6月3日

OF ALL THE medical challenges that scientists have faced, Alzheimer's disease, the most common form of dementia, has been one of the trickiest. Between 1995 and 2021 private money spent on Alzheimer's research totalled $42.5bn, but more than 140 trials failed to deliver a single drug capable of slowing the disease. Yet the tide may be turning. There are two working drugs, offering modest benefits, on the market. A new review paper suggests more could soon follow.

⋯ 继续阅读请开通会员 ⋯